Welcome to our dedicated page for Rocket Lab Usa SEC filings (Ticker: RKLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Lab Corporation (Nasdaq: RKLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a U.S. public company. These documents include current reports on Form 8-K, proxy statements, and other filings that describe material events, governance matters, capital markets activity, and acquisitions.
Rocket Lab’s Form 8-K filings cover topics such as quarterly financial results, executive and director changes, equity offering arrangements, and significant transactions. Examples include reports of results of operations for specific quarters, the adoption of a senior executive cash incentive bonus plan, the establishment of an at-the-market equity offering program under a shelf registration statement, and the completion or announcement of acquisitions such as the purchase of the parent holding company of GEOST LLC and an agreement to acquire all shares of Mynaric AG.
The company’s proxy statement on Form DEF 14A provides detail on board structure, director elections, executive compensation, equity plans, and stockholder voting matters. It also describes the holding company reorganization that made Rocket Lab Corporation the parent of Rocket Lab USA, Inc., and outlines proposals presented to stockholders at the annual meeting.
Through these filings, investors can review information about capital raising (including at-the-market offerings), governance and compensation policies, acquisition terms, and other material corporate events. Real-time updates from EDGAR allow users to see new 8-Ks and related exhibits as they are filed.
Stock Titan’s platform associates these filings with AI-powered summaries that explain the key points of lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership, or the structure of significant transactions. Users can also track how Rocket Lab uses registration statements and resale prospectus supplements in connection with share issuances tied to acquisitions.
Rocket Lab Corporation entered into an equity distribution agreement that allows it to offer and sell, from time to time, shares of its common stock with an aggregate offering price of up to $1,000,000,000.
Sales may be made through multiple investment banks as sales agents or principals, and via complex forward sale structures. These include “Initially Priced Forward Transactions” and “Collared Forward Transactions,” where forward purchasers borrow and sell shares to hedge their exposure and Rocket Lab later settles in cash or stock. The program runs off an effective Form S-3 shelf registration and can be terminated at any time by Rocket Lab or the sales agents.
Rocket Lab Corporation is registering and may sell up to $1,000,000,000 of its common stock via an "at-the-market" equity distribution agreement with multiple sales agents and related forward sale structures.
The prospectus supplement terminates a prior $750,000,000 sales agreement and permits sales through sales agents acting as agents or principals, as well as forward transactions ("initially priced" and "collared" forwards) with specified forward purchasers. Proceeds from initially priced and collared forward transactions are expected to be received on physical settlement or certain prepayment dates; cash or net-share settlement is possible and may result in payments by Rocket Lab or issuance of shares. Commissions to sales agents and forward sellers may be up to 2.0%. The company’s common stock trades on Nasdaq under the symbol RKLB; last reported sale price was $71.31 per share on March 16, 2026.
Rocket Lab Corporation plans to hold its 2026 annual meeting of stockholders on May 20, 2026. Because this date is more than 30 days earlier than the 2025 meeting anniversary, the company has set a new deadline for stockholder proposals and director nominations.
Stockholder proposals submitted under Rule 14a-8 and any director nominations or other business brought under the company’s bylaws must be received by the Company’s Secretary at its Long Beach, California headquarters by March 22, 2026 to be considered for the 2026 proxy materials and meeting.
Rocket Lab Corp director Merline Saintil reported an open-market sale of common stock. On the reported date, she sold 18,126 shares at a weighted-average price of $75.0398 per share in multiple transactions within a narrow price range.
After this sale, Saintil directly holds 261,903 Rocket Lab common shares. The filing notes that the reported price reflects a weighted average and that detailed trade prices within the $75.0000–$75.0950 range are available upon request.
Merline A. Saintil reported reported sales of common stock under Rule 144. The filing lists four transactions totaling 37,500 shares sold on specific dates: 15,000 shares on 12/12/2025 for $975,000.00; 5,000 shares on 12/17/2025 for $272,064.50; 5,000 shares on 12/19/2025 for $324,743.50; and 12,500 shares on 01/14/2026 for $1,124,368.50.
The broker listed is Morgan Stanley Smith Barney LLC and the transactions are described as sales of common stock; the filing notes restricted stock vesting under a registered plan with a referenced date 06/14/2023.
Rocket Lab Corp Chief Financial Officer Adam C. Spice reported multiple open-market sales of common stock on March 2, 2026. The transactions, made under a pre-arranged Rule 10b5-1 plan, sold 62,744 shares mainly to cover tax withholding from vested restricted stock units. Sale prices were reported as weighted averages, with underlying trades occurring in ranges between $66.4700 and $70.9450 per share.
Rocket Lab Corp’s Chief Operations Officer Frank Klein reported open-market sales of 81,250 shares of common stock on March 2 and 4, 2026. These transactions were executed as Rule 10b5-1 trading plan sales, including a sell-to-cover sale to satisfy tax withholding tied to vested restricted stock units.
The shares were sold at weighted-average prices reported in ranges from $66.47 to $73.99 per share across multiple trades. After these transactions, Klein directly held 1,088,237 Rocket Lab shares, reflecting his remaining equity stake in the company.
Rocket Lab Corp senior vice president and general counsel Arjun Kampani reported selling a total of 52,472 shares of Rocket Lab common stock in open-market transactions. The sales occurred on March 2 and March 4, 2026 at weighted-average prices generally in the mid-$60s to low-$70s per share. Part of the sale was a sell-to-cover transaction under a Rule 10b5-1 election to satisfy tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units. The remaining sales occurred automatically under a Rule 10b5-1 trading plan adopted on September 19, 2025. After these trades, Kampani directly owned 397,988 Rocket Lab common shares.
Rocket Lab Corp CEO Peter Beck reported multiple stock sales linked to tax withholding. On March 2, 2026, he sold a total of 18,857 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 plan.
According to the disclosure, these were “sell-to-cover” trades to satisfy applicable tax withholding obligations from vesting and settlement of previously granted restricted stock units. The sales were executed at weighted-average prices, with underlying trade prices ranging from $66.47 to $70.945 per share. After these sales, Beck directly owned 884,085 Rocket Lab shares.
Frank Klein reported restricted stock unit holdings and recent dispositions of common stock in a Form 144 disclosure. The filing lists 36,768 Restricted Stock Units with an effective date of 03/01/2026 and shows common shares sold during the past three months: 44,482 shares on 03/01/2026 and 100,000 shares on 01/02/2026. The trades are reported through Morgan Stanley Smith Barney LLC on 03/04/2026.